Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06119464

Re-Purposing the Ordering of 'Routine' Laboratory Tests in Hospitalized Medical Patients (RePORT Study)

Laboratory test overuse occurs when tests are ordered repetitively, without due consideration of impact on clinical status. Repetitive inpatient lab testing often provides limited value for patient outcomes while increasing healthcare costs, patient discomfort, and unnecessary transfusions and prolonging hospitalizations. The research study aims to reduce laboratory test overuse in hospitals through implementation of a comprehensive, multi-disciplinary, and multi-faceted intervention bundle that includes audit and feedback reports, clinician education, clinical decision support tool, and patient infographics across 14 hospitals in Alberta.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Calgary

Calgary, Alberta, T2N 1N4, Canada

About this study

Background: Laboratory and Pathology testing contributes to rising health care expenditure. A relatively large percentage (up to 42%) of laboratory testing can be considered wasteful. Redundant testing alone has been estimated to waste up to 5 billion dollars annually in the United States of America. Laboratory over-utilization leads to false positives that promotes further inappropriate testing and procedures, interruption of normal sleep pattern of inpatients, as well as iatrogenic anemia and pain. A Canadian study showed significant hemoglobin reductions as a result of phlebotomy. Studies support the safe reduction of repetitive laboratory testing without negative effects on adverse events, readmission rates, critical care utilization, or mortality.

The aim of this research study is the following:

  • To implement a multimodal intervention bundle containing healthcare provider and patient engagement tools for hospitalized medical inpatients in 14 hospitals across the province of Alberta in Canada using a cluster randomized stepped-wedge design
  • To evaluate the impact of the intervention bundle on laboratory test utilization of six target laboratory tests (complete blood count, electrolytes, creatinine, urea, partial thromboplastin time, and international normalized ratio), costs, and patient safety outcomes.

This intervention bundle will be implemented across all the adult hospital sites in Alberta starting January 2023 and evaluated until October 2024.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • all participants (patients and healthcare providers) within enrolled adult hospitals in Alberta of medical and hospitalist units during study period

Exclusion criteria

  • outside of the above-mentioned province
  • hospitals not enrolled
  • non-medical units (eg. ICU, surgical, pediatric, obstetrical units)

Treatment and study plan

Multimodal Intervention: Education

Other

The multimodal intervention bundle consists of education, audit and feedback, patient engagement, and system changes.

Multimodal Intervention: Audit and Feedback

Other

The multimodal intervention bundle consists of education, audit and feedback, patient engagement, and system changes.

Multimodal Intervention: Patient Engagement

Other

The multimodal intervention bundle consists of education, audit and feedback, patient engagement, and system changes.

Multimodal Intervention: System Changes

Other

The multimodal intervention bundle consists of education, audit and feedback, patient engagement, and system changes.

Primary outcomes

  1. Number of routine laboratory tests ordered per patient-day in the intervention versus control periods

    Time frame: 1 year 9 months

    Number of the six target laboratory tests (complete blood count, electrolytes, creatinine, urea, international normalized ratio and partial thromboplastin time) ordered per patient-day

Secondary outcomes

  1. Costs associated with routine and all common laboratory test ordered

    Time frame: 1 year 9 months

    Costs of test and associated costs with and without intervention

  2. Proportion of hospital patient lab-free days

    Time frame: 1 year 9 months

    Number of hospital patient-days not associated with laboratory blood draws

  3. Proportion of critically abnormal test results

    Time frame: 1 year 9 months

    As defined by lab standards, we will track the proportion of critically abnormal test results

  4. Length of stay

    Time frame: 1 year 9 months

    Patient length of stay on the unit

  5. Transfer to Intensive Care Unit

    Time frame: 1 year 9 months

    Transfer rate to Intensive Care Unit

  6. In-patient and 30-day patient mortality over study period

    Time frame: 30 days post discharge

    Mortality rate in hospital and at 30-days post discharge

  7. 30-day post discharge readmission rate

    Time frame: 30 days post discharge

    Hospital re-admission within 30 days post discharge

  8. Number of all common laboratory tests

    Time frame: 1 year 9 months

    Number of all common laboratory tests (tests that contribute to >80% of hospital laboratory test utilization during study period) per patient-day.

Sponsors and collaborators

Lead sponsor

University of Calgary

Other

Collaborators

  • Alberta Health services
  • Canadian Institutes of Health Research (CIHR)
  • University of British Columbia

Registry information

Important dates

Study start
2023
Primary completion
2024
Study completion
2026
First posted
Nov 7, 2023
Registry last updated
May 27, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.